ライフサイエンスコーパス: Fab

1 Fab-N-linked-glycosylation introduction sites are observ

2 Fabs offer an attractive platform for monoclonal antibod

3 Structurally, 78/2 and 69/1 Fabs bound the globular head or base of the head domain

4 The HT-2 toxin and anti-HT2 (10) Fab reaction was reported by anti-HT2 immune complex sin

5 binding fragment of antibody (anti-HT2 (10) Fab).

6 MET crystal structure shows that the 107_A07 Fab comes into close proximity with the HGF/SF-binding S

7 Five X-ray structures of ch28/11 Fab complexes with the SSEA-4 glycan headgroup, determin

8 The structure shows that ZIKV-117 Fabs cross-link the monomers within the surface E glycop

9 ted more from PEGylation than the anti-IL-13 Fab' did.

10 dence time of the anti-IL-17A and anti-IL-13 Fab' fragments in the lungs but PEGylation was able to p

11 f delivery of the anti-IL-17A and anti-IL-13 Fab' fragments within the lungs had a major impact on th

12 ure of pro-myostatin in complex with 29H4-16 Fab, a high-affinity variant of SRK-015, at 2.79 angstro

13 s residence time as well and the anti-IL-17A Fab' benefited more from PEGylation than the anti-IL-13

14 fect on the residence time of an anti-IL-17A Fab' fragment in the lungs of mice.

15 Finally, using I(125)-labeled anti-IL-17A Fab', we showed that the protein fragment hardly penetra

16 The footprint of the ZIKV-195 Fab fragment expands across two adjacent envelope (E) pr

17 Guided by the structure of the 237 Fab:Tn-OTS8-glycopeptide complex, here we conducted a de

18 n X-ray crystal structure of an FcRn-DX-2507 Fab complex, revealing a nearly complete overlap of the

19 a domain-swapped Fab dimer from among >3000 Fab crystal structures determined to date.

20 achieved through direct binding of MEDI-579 Fab to the reactive centre loop (RCL) of PAI-1 and at th

21 inding to BMS-986010 (which contains the 7B7 Fab, where Fab is fragment antigen-binding region of an

22 ic scaffold (Bipod) comprising an scFv and a Fab on a heterodimeric Fc eliminates the possibility of

23 We applied a Fab-based live endogenous modification labeling techniqu

24 ostatin, proteins, and antibodies, such as a Fab arm of the antibody Herceptin and a designed antibod

25 rd open (O(o)) conformation, stabilized by a Fab fragment, and a ligand-bound inward-facing (I(f)) co

26 A separate structure of CD73 with a Fab (TB38) which complements TB19 in a particularly pote

27 structure of the allergen in complex with a Fab from the murine IgG mAb 7A1 that binds an epitope ov

28 s have a 2-fold higher propensity to acquire Fab glycans compared with IgG1 or IgA.

29 A high-affinity Fab was selected from one of the libraries and converted

30 Particularly, anti-Alp2 Fab A4A1 had a binding affinity of 11 nM and inhibition

31 rogation of intact antibodies or F(ab')2 and Fab fragments has the potential to significantly streaml

32 nd the antigen binding fragments F(ab')2 and Fab) targeting epidermal growth factor receptor were lab

33 d domain interactions for IgG antibodies and Fab fragments in the structural database.

34 rful platform for multimerizing antibody and Fab fragments to enhance the capabilities of human thera

35 riable H (VH) and variable L (VL) chains and Fab-N-linked glycosylation in RA synovial B cell clones

36 as heavy chains to form antibody dimers and Fab heavy chains to form Fab tetramers.

37 s as markers for average positions of Fc and Fab of antibodies on the beads.

38 Parallel profiling of whole, Fc, and Fab domain-specific IgG glycosylation pointed to enhance

39 rms (single-chain Fab in Pichia pastoris and Fab in Escherichia coli).

40 ized polyclonal immunoglobulin Gs (IgGs) and Fabs from COVID-19 convalescent individuals for recognit

41 Antibody Fab fragments have been exploited with significant succe

42 ptamine 2B (5-HT2B) receptor and an antibody Fab fragment bound to the extracellular side of the rece

43 interested in the codon usage of an antibody Fab fragment gene exhibiting extreme toxicity in the E.

44 CyRPA alone and in complex with an antibody Fab fragment.

45 e heavy chain and light chain of an antibody Fab.

46 at the SLE sample has many dominant antibody Fab-related mass features unlike the healthy controls.

47 are functionalized with anti MC-LR antibody Fab' fragments for the selective capture of MC-LR from a

48 latform to characterize total serum antibody Fabs in a systemic lupus erythematosus (SLE) patient sam

49 f two Fab' fragments, one from 1F5 antibody (Fab'1F5), the other from Rituximab (Fab'RTX).

50 to a stabilized dimer of different antitumor Fabs.

51 rfaces are, on average, at least as polar as Fab surfaces.

52 x, incorporation of a miniPEG spacer between Fab' and MORF1 and between polymer backbone and pendant

53 e lengths that connect their antigen-binding Fab and effector-binding Fc regions.

54 expressing cells using tagged, apex-binding Fab PG16 and determined the structure of the PG16-Env co

55 s study, we have developed an HtrA1-blocking Fab fragment to test the therapeutic hypothesis that Htr

56 AMD who were treated with the HtrA1-blocking Fab fragment.

57 f monomers and dimers, as enumerated by bNAb Fab binding using single-particle electron microscopy an

58 it/human monoclonal antibody fragments (both Fab and scFv) against rHBeAg.

59 ls by antibodies traditionally requires both Fab and Fc domains of IgG.

60 d domain and is partly occluded by the bound Fab in the crystal structure.

61 functioning of the Bithorax complex boundary Fab-7, interacts specifically with a special class of CE

62 n-antigen-specific IgG, bulk Fc domain, bulk Fab domain, and purified protein derivative (PPD)- and A

63 nal antibodies against CD73 was generated by Fab-arm exchange.

64 e binding could specifically be inhibited by Fab anti-C1q and C1q-derived peptides.

65 nd imaged hemichannels that were liganded by Fab-epitope antibody fragments via atomic force microsco

66 more, imaged Cx26/Cx30-HA triple liganded by Fab-HA showed multiple arrangements that can be derived

67 therapy vector but is partially restored by Fab virus shielding.

68 The crystal structure of C585 Fab in complex with the HA from A/Switzerland/9715293/20

69 The caterpillar-shaped (catSP) Fab C10:ZIKV complex shows Fabs locking the E protein ra

70 g anchor on surface receptor CD20 (anti-CD20 Fab' conjugated with a morpholino oligonucleotide 1) and

71 onucleotide (MORF1) attached to an anti-CD20 Fab' fragment (Fab'-MORF1); (2) multiple copies of compl

72 Thus, masking the anti-CD3 Fab fragment with an anti-idiotypic mask and cleavage of

73 ypic anti-CD3 mask connected to the anti-CD3 Fab through a tumor protease-cleavable linker.

74 in variable fragment (ScFv) into an anti-CD3 Fab.

75 essed as two recombinant forms (single-chain Fab in Pichia pastoris and Fab in Escherichia coli).

76 ically significant difference when comparing Fab'1F5-MORF1 with Fab'RTX-MORF1.

77 nt of antibody type and site of conjugation (Fab and Fc) in preclinical studies.

78 d glycinergic currents compared with control Fab-IgG.

79 any platforms for creating bsAbs, controlled Fab-arm exchange (cFAE) has proven useful based on minim

80 distinct bispecific molecules by controlled Fab-arm exchange (DuoBody technology).

81 whole panel of bsAbs produced by controlled Fab-arm exchange.

82 We recently described controlled Fab-arm exchange (cFAE) as an easy-to-use method for the

83 MBG bound to a KoH Fab versus a conventional Fab showed that the KoH body has a much deeper binding p

84 doubling the effective size of conventional Fab-protein complexes for cryoEM.

85 Unlike conventional Fabs, which are monovalent monomers, Fab HC84.26.5D asse

86 s has highlighted the importance of coupling Fab neutralization with Fc effector activity for effecti

87 chemically programmed antibody fragment (cp-Fab) as on/off switch.

88 In proof-of-concept studies, this cp-Fab/CAR-T system targeting folate binding proteins on th

89 onfirms that incubation of spike with CR3022 Fab leads to destruction of the prefusion trimer.

90 light-sheet fluorescence microscopy with Cy5-Fab-PAS200 confirmed better tracer extravasation in the

91 of the complex between an omalizumab-derived Fab and IgE-Fc, with one Fab bound to each C3 domain.

92 hat the highly identifiable shape of dimeric Fab HC84.26.5D makes it useful as a fiducial marker for

93 greement with the crystal structure, dimeric Fab HC84.26.5D is able to bind two HCV E2 molecules in s

94 oter (GBid) - for constructing phage display Fab libraries.

95 antibodies (mAbs) from large phage-displayed Fab, scFv, and VH libraries by panning against the recep

96 The proximal and the distal Fabs are rigidly tethered to the Fc.

97 (177)Lu-DOTA-Fab-PEG24-EGF bound specifically to HER2 and EGFR on tum

98 (177)Lu-DOTA-Fab-PEG24-EGF inhibited tumor growth more effectively th

99 t TrR1 tumors were treated with (177)Lu-DOTA-Fab-PEG24-EGF or (111)In-DTPA-Fab-PEG24-EGF at the NOAEL

100 The maximum injected amount of (177)Lu-DOTA-Fab-PEG24-EGF that caused no observable adverse effects

101 The tumor uptake of (177)Lu-DOTA-Fab-PEG24-EGF was 2-fold greater than (177)Lu-DOTA-trast

102 ormal tissue biodistribution of (177)Lu-DOTA-Fab-PEG24-EGF was studied at 48 h after injection in ath

103 h (177)Lu-DOTA-Fab-PEG24-EGF or (111)In-DTPA-Fab-PEG24-EGF at the NOAEL, or with unlabeled immunoconj

104 or growth more effectively than (111)In-DTPA-Fab-PEG24-EGF because of a 9.3-fold-higher radiation-abs

105 ticle, and empty particle-and show that each Fab can simultaneously occupy the mature virion.

106 Elevated Fab glycosylation represents an additional hallmark of T

107 EY6A Fab binds the receptor binding domain (RBD) of the viral

108 -resolution crystal structure of an RBD-EY6A Fab complex identifies the highly conserved epitope, awa

109 of the pre-fusion spike incubated with EY6A Fab reveal a complex of the intact spike trimer with thr

110 of Fab marker peptides found divided by Fc + Fab marker peptides x 100%.

111 tion of IgG, possibly due to a less flexible Fab, positioned closer to the Fc portion.

112 y immobilized antibodies digestion rates for Fab and Fc peptides were similar.

113 function appropriately when substituted for Fab-7: it blocks crosstalk but does not support bypass.

114 antibody dimers and Fab heavy chains to form Fab tetramers.

115 and structural data, we determine that four Fabs simultaneously occupy four exosites on the beta-try

116 An antibody fragment (Fab) of MAb E was found to neutralize the virus at low m

117 structure of the COVA1-16 antibody fragment (Fab) with the SARS-CoV-2 receptor-binding domain (RBD) a

118 te residing in the antigen-binding fragment (Fab or Fv) is an autonomous and complete unit for antige

119 onoclonal antibody antigen-binding fragment (Fab) mixture, demonstrating the feasibility to separate

120 complexed with the antigen-binding fragment (Fab) of a human neutralizing antibody, 860-55D.

121 gth antibody or an antigen-binding fragment (Fab).

122 RF1) attached to an anti-CD20 Fab' fragment (Fab'-MORF1); (2) multiple copies of complementary oligon

123 dopt a methodology using antibody fragments (Fab) conjugated to gold nanoparticles (immunogold) to ma

124 matted as soluble antigen-binding fragments (Fab), these clones expressed well, were predominantly mo

125 Crystal structures of antibody fragments (Fabs) 311 and 317 with an (NPNA)3 peptide illustrate the

126 ed a series of synthetic antibody fragments (Fabs) against different conformations of betaarrs from p

127 ody derivatives, such as antibody fragments (Fabs) and single-chain variable fragments (scFvs), are n

128 play library to engineer antibody fragments (Fabs) that can modulate the activity of the enzyme isoci

129 s of both sets of antigen-binding fragments (Fabs) and preserves steric accessibility to receptor-bin

130 P1 bound to three antigen-binding fragments (Fabs) of the clinically used antibody mAb120.545.

131 ), and monovalent antigen-binding fragments (Fabs) to investigate how affinity maturation contributes

132 bound by two RTX antigen-binding fragments (Fabs), each of which engages a composite epitope and an

133 antibody (5-100 mug/ml) or de novo generated Fabs (20 mug/ml) inhibited TNBC cell growth in vitro.

134 oduce a strictly monovalent anti-TCRbeta H57 Fab' ligand that, when coupled to a supported lipid bila

135 f ADCs conjugated at different sites (LC, HC-Fab, and HC-Fc) with various classes of payload-linkers.

136 composite epitope and an extensive homotypic Fab:Fab interface.

137 ghlight the potential relevance of homotypic Fab:Fab interactions in targeting oligomeric cell-surfac

138 Bid, we constructed a chimeric chicken-human Fab phage display library comprising 10(10) variants tar

139 ependent antibodies in chimeric rabbit/human Fab format and validated it by next-generation sequencin

140 The toxic synthetic human Fab gene contained domains optimized by the "one amino a

141 s after 4CMenB immunization revealed 2 human Fabs (huFabs) (1A12, 1G3) with some crossreactivity for

142 ize structural changes in a native humanized Fab A33 antibody fragment, that correlated with the expe

143 ral potential applications for the humanized Fab/scFv.

144 ctures of intact IgE suggesting that the IgE Fab is fixed relative to the Fc.

145 Ag layer sufficiently sized for a single IgG Fab to access.

146 somatic mutations such that monovalent IgG4 Fab-arm-exchanged autoantibodies reach a high-affinity t

147 hich further interacts with the adjacent IgM-Fab(2) and globular C1q-recognition unit.

148 binds to several BX-C boundaries, including Fab-7 and Mcp To study Pita functions, we have used a bo

149 s and antibody-derived constructs (including Fab, Fc-fusions and bispecifics) in mammalian cells.

150 ion considerably reduced toxicity, increased Fab expression from negligible levels to 10 mg/l, and re

151 the membrane, and only around 100 individual Fab':TCR interactions are necessary to stimulate early T

152 an IgG1 antibodies were cleaved rapidly into Fab and smaller fragments, pointing to specific regions

153 of crystal structures of MBG bound to a KoH Fab versus a conventional Fab showed that the KoH body h

154 transfer measurements with two dual-labeled Fabs.

155 STED imaging of fluorescently labeled Fabs reveals a common pattern of native Env recognition

156 Der p 2 as well as complexes of ligelizumab-Fab with IgE and IgE Fc were assessed by negative stain

157 The combination of intact mAb, Fab, or F(ab')2 mass, intact LC and Fd masses, and CDR3

158 es on MBs, restricting proteolysis to mainly Fab regions.

159 than the subnanomolar affinity of the mature Fabs.

160 o-EM) structure of a neutralizing monoclonal Fab-spike complex revealed an epitope that blocks ACE2 r

161 ntional Fabs, which are monovalent monomers, Fab HC84.26.5D assembles into a bivalent domain-swapped

162 C and unlike bivalent antibodies, monovalent Fab'-DNA triggers TCRs only when physically coupled to t

163 Moreover, monovalent Fab fragments generated from the purified IgG of three o

164 In the presence of heparin, the monovalent Fab shows essentially no inhibition, whereas the bivalen

165 Mature mAbs, UCA mAbs, and mature monovalent Fabs bound to MuSK and demonstrated pathogenic capacity.

166 plexes display a compact rsCSP with multiple Fabs bound, with the rsCSP-Fab311 complex forming a high

167 le refinement approach, we resolved an MuPyV:Fab complex map to 3.2 angstrom resolution.

168 essed using a metric R(o) denoting amount of Fab marker peptides found divided by Fc + Fab marker pep

169 In the case of Fab-7, we used a novel sensitized background to show tha

170 ppeared to originate from the interaction of Fab and IgG1 in small soluble oligomers, or through the

171 This vector design reduces the process of Fab library construction to "scFv-like" simplicity and t

172 nd 3D electron microscopy reconstructions of Fab-trimer complexes revealed a horizontal binding angle

173 genic electron microscopy reconstructions of Fab:CHIKV complexes at 4- to 5- angstrom resolution.

174 Removal of Fab-linked glycans in RA056/11.23.2 in the N-mutant coun

175 ) are functionally monovalent as a result of Fab-arm exchange.

176 The helical tail structure of Fab C10:DENV3 clubSP showed although the Fab locked an E

177 Three cryoelectron microscopy structures of Fab in complex with Ross River (RRV), Mayaro, or chikung

178 Crystal structures of Fab-AbetapE3 complexes revealed two distinct binding mod

179 or A, show a previously unrecognized type of Fab-Fc orientation with a distorted lambda-shape in whic

180 werful tool for the discovery/engineering of Fabs and IgGs.

181 sal strategy to enhance the success rates of Fabs as structure determination chaperones.

182 Studies of omalizumab Fab binding in solution demonstrate the allosteric basis

183 n with a distorted lambda-shape in which one Fab-arm is oriented toward the Fc portion.

184 omalizumab-derived Fab and IgE-Fc, with one Fab bound to each C3 domain.

185 e was directly blocked by either PA50 mAb or Fab and suggested that receptor blockade is the mechanis

186 less to folded state stability than in other Fab domains.

187 oriented antibodies, the peptides from outer Fab regions gave a much higher digestion rate than those

188 ncreased binding/neutralization of IgGs over Fabs.

189 A crystal structure of two PA50 Fabs bound to a segment of the TcdA CROPs helped define

190 olved in the prolonged presence of PEGylated Fab' in the airway lumen might include binding to the mu

191 ssment of FR104 (n=5), a selective pegylated Fab' antibody fragment antagonist of CD28 that does not

192 examined specificities of polyclonal plasma Fabs, revealing recognition of both S1(A) and RBD epitop

193 result of the binding of multiple polyclonal Fabs to the C region of primary IgH.

194 was validated using previously recalcitrant Fab-antigen complexes where introduction of an engineere

195 ent on the heavy chain (HC) variable region (Fab) and the other present on the conserved HC constant

196 herapeutic monoclonal antibody and a related Fab fragment, were combined to investigate the impact of

197 fferent from that of the previously reported Fab 2G12 dimer.

198 of pilus-1 adhesive properties but required Fab-dependent recognition of RrgB, the pilus shaft prote

199 l conformation of IgE, which retains a rigid Fab-Fc architecture.

200 ntibody (Fab'1F5), the other from Rituximab (Fab'RTX).

201 lly, we engineer mouse hybridomas to secrete Fab' fragments instead of the whole Ig.

202 ver, the architecture of the doughnut-shaped Fab HC84.26.5D dimer is completely different from that o

203 A short (Fab)trastuzumab-derived peptide specific for HER2 recept

204 ar-shaped (catSP) Fab C10:ZIKV complex shows Fabs locking the E protein raft structure containing thr

205 fied by PG9, bind asymmetrically as a single Fab to the apex of the symmetric Env trimer using a prot

206 In solution, Fab HC84.26.5D exists predominantly as a dimer (~80%) in

207 We show that a conformation-specific Fab can reactivate an IDH1 mutant associated with brain

208 refore utilize their TCR like a cell-surface Fab repertoire, somewhat analogous to engineered chimeri

209 only the second example of a domain-swapped Fab dimer from among >3000 Fab crystal structures determ

210 Bivalent domain-swapped Fab dimers engineered on the basis of HC84.26.5D may als

211 y engineering strategy to generate synthetic Fab variants that significantly reduces elbow flexibilit

212 The structure of the TB19 Fab with CD73 reveals that it blocks alignment of the N-

213 The near-atomic structure also revealed that Fab binding had caused capsid destabilization in regions

214 of Fab C10:DENV3 clubSP showed although the Fab locked an E protein dimer, the dimers have shifted l

215 affinity-optimized versions of B7-H6 and the Fab arm derived from cetuximab.

216 ion of therapeutic monoclonal antibodies-the Fab domains bind the antigens on the target cell, wherea

217 ing an oriented immobilization approach, the Fab' fragments are covalently attached to gold surface t

218 n of the Hox genes Ubx, abd-A, and Abd-B The Fab-7 boundary is located between the iab-6 and iab-7 do

219 resolution of 2.5 A of a complex between the Fab fragments of E1 and HM14c10 and provide the first de

220 resolution of 2.5 A of a complex between the Fab fragments of E1 and HM14c10 provides the first detai

221 require the coordinated function of both the Fab and Fc domains(1).

222 n of individual glycan species from both the Fab and Fc N-Linked glycosylation sites is consistent wi

223 ure of the nAChR alpha1 subunit bound by the Fab fragment of mAb35, a reference monoclonal antibody t

224 y require tandem virus neutralization by the Fab moiety and effector functions of the Fc region.

225 tion of virus neutralization mediated by the Fab.

226 30 or Cx30-HA/Cx26 heteromeric channels, the Fab-HA binding distribution was binomial with a maximum

227 rategy by substituting modified DNAs for the Fab-7 boundary, which is located between the iab-6 and i

228 ect evaluated deuterium uptake data from the Fab fragment of NISTmAb reference material (PDB: 5K8A )

229 ow that an ~200-bp sequence of dHS1 from the Fab-7 boundary rescues the bypass defects of these multi

230 FWR mutations in the Fab elbow region are frequently observed in HIV-1 bnAbs

231 Thus, selection of mutations in the Fab elbow region impacts interdomain conformational flex

232 ific ADCs with linker-drug conjugated in the Fab region.

233 ure of the binding arms, particularly in the Fab-scFv-Fc format.

234 In combating viral infections, the Fab portion of an antibody could mediate virus neutraliz

235 n equilibrium with the monomeric form of the Fab (~20%).

236 for 430 proteolytic peptide sequences of the Fab fragment (~78 900 centroids), giving ~100% coverage,

237 structure to 1.8 angstrom resolution of the Fab fragment of an affinity-matured human monoclonal ant

238 Here, we present the structure of the Fab fragment of such an antibody.

239 cket formed between VH and VL domains of the Fab fragments.

240 For some of the Fab gene variants, we also observed striking differences

241 We redesigned five segments of the Fab gene with a "codon harmonization" method described b

242 " by E1 by increasing its recognition of the Fab HM14c10 light chain CDRs.IMPORTANCE A chimeric yello

243 and determined the crystal structure of the Fab in complex with its target, which identifies the bin

244 onal antibodies to be the CDR H3 loop of the Fab region, and show that they all have nano to micromol

245 t in each of the 2 branches, the rest of the Fab reorients specifically, from its position in the HA-

246 The nature of the Fab' fragment had an influence on its residence time as

247 ink the constant and variable domains of the Fab, can introduce disorder and thus diminish their effe

248 Overlay of the Fab-MET crystal structure with the InternalinB-MET cryst

249 the crystal structure at 2.4 angstrom of the Fab/RBD complex.

250 Several of the Fab/scFv, expressed in Escherichia coli, had unprecedent

251 Placing the only purification tag on the Fab ensured that the isolated Env was continuously stabi

252 alactose-alpha-1,3-galactose, located on the Fab region of cetuximab, was identified as the target re

253 tigens and Protein L (PrL, which targets the Fab region of the antibody), respectively, labeled with

254 coupling of antigen specificity through the Fab domain to signal transduction via Fc-Fc receptor int

255 l means of antigen recognition, in which the Fab fragment of an antibody acts as an adaptor, linking

256 ecule, two on each heavy chain, of which the Fab glycans have been reported to be complex and multipl

257 While the Fab domains mediate highly specific antigenic recognitio

258 /2013, French Polynesia) in complex with the Fab fragment of a highly therapeutic and neutralizing hu

259 rus-like particles (VLPs) complexed with the Fab of a human neutralizing antibody.

260 In GBid, the constant domains of the Fabs are located in the backbone of the phagemid vector

261 the orientation of the fusion domain on the Fabs.

262 Pairing the Fabs of parents with nonoverlapping epitopes was both su

263 ase-like conformation and interacts with the Fabs through its extracellular helices.

264 ater separation between the centers of their Fab regions than those for IgG4, in agreement with their

265 Several of these Fabs allosterically and selectively modulated the intera

266 Interestingly, one of these Fabs selectively disrupted betaarr-clathrin interaction,

267 nces between rHBeAg and HBeAg, we used these Fabs in microscale immunoaffinity chromatography to puri

268 ibution was binomial with a maximum of three Fab-HA bound.

269 omplex of the intact spike trimer with three Fabs bound and two further multimeric forms comprising t

270 been shown to be antigenic when attached to Fab oligosaccharides of monoclonal antibodies (mAbs) , w

271 omprising the destabilized spike attached to Fab.

272 we determined the structure of tralokinumab Fab in complex with human IL-13 to 2 A resolution.

273 2-fold greater than (177)Lu-DOTA-trastuzumab Fab or (177)Lu-DOTA-EGF.

274 fic (177)Lu- and (111)In-labeled trastuzumab Fab or EGF killed tumor cells that predominantly express

275 one and pendant MORF2, and comparison of two Fab' fragments, one from 1F5 antibody (Fab'1F5), the oth

276 antigen-antibody structure in which the two Fab arms of a single antibody occupy the two arm regions

277 e antibody mimic was prepared by linking two Fabs from the therapeutic antibody trastuzumab, which ar

278 Crystal structures of two Fabs revealed how mutations acquired during affinity mat

279 recognition by the new bNAb BG1 in which two Fabs bind asymmetrically per Env trimer using a compact

280 However, monovalent UCA Fabs bound to MuSK but did not have measurable pathogeni

281 Affinity of the UCA Fabs for MuSK was 100-fold lower than the subnanomolar a

282 pecific antibodies (BsAbs) having two unique Fab domains requires heterodimerization of the two heavy

283 We used Fab/scFv in the context of an enzyme-linked immunosorben

284 resulted in similar expression of anti-VEGF Fab and similar suppression of VEGF-induced vascular lea

285 -314, an AAV8 vector expressing an anti-VEGF Fab, suprachoroidal injection of the same dose of RGX-31

286 effects of these changes on cell viability, Fab yield and display on filamentous phage using differe

287 whereas the IgG4 isotype can undergo in vivo Fab arm exchange leading to bispecific antibody and off-

288 MS-986010 (which contains the 7B7 Fab, where Fab is fragment antigen-binding region of an antibody),

289 structure of the ZIKV virion in complex with Fab fragments of the potently neutralizing human monoclo

290 tructures of the EV71 virion in complex with Fab fragments of these potent and protective antibodies

291 structures of the allergens in complex with Fab fragments of three murine mAbs that interfere with I

292 under virus (CRF01_AE T/F100) complexed with Fab from the broadly neutralizing antibody (bNAb) 8ANC19

293 However, treatment of Y7A KI mice with Fab' fragments of the function-blocking anti-CLEC-2 anti

294 difference when comparing Fab'1F5-MORF1 with Fab'RTX-MORF1.

295 opted hexagonal, dome-shaped structures with Fab pairs, dimerized by hinge domains, bound to surface

296 Complex formation of DENV and ZIKV with Fab C10 stabilize the viruses allowing cryoEM structural

297 ortened CSP (rsCSP) construct saturated with Fabs.

298 alizing antibodies with RBD, with or without Fab CR3022, at 2.33- to 3.20-angstrom resolution reveale

299 asymmetric Protein A binding, and the scFv x Fab format.

300 ZKA190 Fab binds all 180 E protein copies, altering the virus q